It has been described that sorafenib inhibits the expression of extracellular matrix proteins—MMP-1 and MMP-9—and increases the level of the adhesive protein—E-cadherin—in breast cancer cells (MCF-7 and MDA-MB-231) [38]. The gene discussed is MMP9; the disease is breast carcinoma.